ABC 1
Natural health product licensed in Canada
- Other names
- ADR 1, Leritone Genius 1, Leritone Santé cognitive- 1, Leritone cerveau 1, Leritone Études 1
- Licence holder
- IRB Yves Ponroy Canada Inc.
- NPN or DIN-HM
- 80022670
- Status
- Active licence
- Licence date
- 3 December 2010
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Gélatine, Ceratonia Siliqua, Glycérine, Dioxyde de titane
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants | minimum: 6 years ; maximum: 9 years | 3 Capsule | 1 day |
| Enfants | minimum: 6 years ; maximum: 9 years | 5 Capsule | 2 days |
| Enfants | minimum: 6 years ; maximum: 9 years | 2 Capsule | 2 days |
Uses authorised in Canada
ABC1 Aide à contribuer à la santé cognitive et aux fonctions cérébrales. ABC 1 Aide à contribuer au développement du cerveau, des yeux et des nerfs chez les enfants âgés de 12 ans et moins. Aide au développement du système nerveux.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80022670
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.